Treatment Access Solution

A collaboration with ARIAD Pharmaceuticals, Inc.

Iclusig (ponatinib)

The Max Foundation and ARIAD Pharmaceuticals, Inc. have established a shared-value collaboration to increase access to Iclusig (ponatinib) for people living with chronic myeloid leukemia (CML) in certain low income countries. This access pathway is specifically designed to respond to spontaneous requests for access on behalf of patients who are uninsured and underinsured, where product is either not available commercially, where significant access hurdles exist and where local market initiatives cannot enable access to the therapy.

Requests for Iclusig (ponatinib) must meet established criteria. View our global map and click on individual countries to learn where this collaboration is operating today. Contact us for more information about access to Iclusig (ponatinib) in these countries.

Return to Treatment Access Solutions